Looming Challenges for ICER in Assessing the Value of Rare Disease Therapies

This report examines why the Institute for Clinical and Economic Review (ICER) and the Quality Adjusted Life Years (QALY) approach to value assessment is particularly ill-suited to assess the cost-effectiveness of orphan and rare disease treatments, which represent a rapidly growing sector of the biopharmaceutical marketplace.

Download Report: Looming Challenges for ICER in Assessing the Value of Rare Disease Therapies

Download One-Pager: [Download not found]